

Submitted For IN0972K1B
Serial No.: 10/028,251
Filed: December 20, 2001



PATENT
CASE IN0972K1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of: :

GUZI ET AL : Examiner: E. Huang

For Patent For: FARNESYL PROTEIN : Group Art Unit: 1625
TRANSFERASE INHIBITORS : Date: July 5, 2001
:
:

Serial No.: 09/465,523 :

Filed: December 16, 1999 :
-----X

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Information about other applications is provided below.

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST
CLASS MAIL IN AN ENVELOPE ADDRESSED TO ASSISTANT
COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON


July 5, 2001
(DATE OF DEPOSIT)

HENRY C. JEANETTE REG. NO. 30,856
(REGISTERED REPRESENTATIVE)

Henry C. Jeanette July 5, 2001
(SIGNATURE AND DATE)


Applicants are submitting a 1449 form citing EP0157399 published October 9, 1985.

Applicants also wish to inform the Examiner of Copending Application Serial No. 09/469,465 filed December 22, 1999 (our Docket No. IN0887K1), claiming priority to Provisional Application No. 60/113,405 filed December 23, 1998, which discloses compounds of the formula:




or a pharmaceutically acceptable salt or solvate thereof, wherein

Q is:



Z represents hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,



heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, or -CY³Y⁴ wherein Y³ and Y⁴ independently represent alkyl and aryl or Y³ and Y⁴, together with the attached carbon atom (-C), can form a cycloalkyl or a cycloalkenyl ring;

R¹, R², R³, R²⁰, R²², R³⁰ and R³² independently represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R²⁵ can represent hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl or -OR⁴⁰ wherein R⁴⁰ can represent alkyl, aryl, arylalkyl,

cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

Y represents aryl, heteroaryl, heterocycloalkyl or cycloalkyl,


t is zero, 1, 2 or 3;

w is zero or 1; and


A is nothing, hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cyano, heteroaryl or heteroarylalkyl.

Y can be an imidazole group.


Example 28S on page 44 discloses the compound:




Example 28T on page 44 discloses the compound:




Example 28Y on page 47 discloses the compounds:



Example 237 on page 71 discloses the compound:



Respectfully submitted,


Henry C. Jeanette
Reg. No. 30,856
Attorney for Applicants
(908) 298-5041



PATENT CASE: IN0972K1B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X	:	
In re Application of: GUZI et al.	:	Examiner: Evelyn Mei Huang
	:	
For Patent: Farnesyl Protein Transferase	:	Date: January 14, 2003
Inhibitors	:	
	:	Group Art Unit: 1625
Serial No.: 10/028,251	:	
	:	
Filed: December 20, 2001	:	
-----X	:	

Schering-Plough Corporation
Kenilworth, New Jersey 07033

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO-1449 Form (one page) listing patents known to Applicants which may be relevant to this application. This Statement is being filed prior to the first substantive Office Action from the Examiner and, therefore, no fee should be due.

Copies of these publications were previously submitted in Applicants' Parent Application Serial No. 09/465,523 filed December 16, 1999 from which this application claims the benefit of. Therefore, copies of these documents are not being submitted herewith. The Examiner is requested to notify the undersigned if copies of the documents are desired.

Documents AB, AC and AQ were cited on a PTO-892 form in Applicant's Parent Application.

Enclosed is a copy of Applicants' PTO-1449 form from an Amendment as well as Applicants' Information Disclosure Statements from Applicants' parent Application.

In re Application of: **Guzi et al.**
Serial No.: 10/028,251
Filed: December 20, 2001

As per 37 CFR 1.97, because the IDS is being filed prior to the mailing of a first office action on the merits, applicants respectfully request consideration of the IDS by the Examiner.

Applicants respectfully request that the cited documents be made of record in the above- identified Application.

Respectfully submitted,

Robert L. Bernstein
Robert L. Bernstein
Reg. No. 46,020
Attorney for Applicants
(908) 298-3985

RLB:sh

**I HEREBY CERTIFY THAT THIS
CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE
AS FIRST CLASS MAIL IN AN ENVELOPE
ADDRESSED TO ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231
ON January 14, 2003**

ROBERT L. BERNSTEIN
(REGISTERED REPRESENTATIVE)

Robert L. Bernstein 1/14/03
(SIGNATURE AND DATE)

Submitted For: N0972K1B
Serial No.: 107028,251
Filed: December 20, 2001

PATENT
CASE IN0972K1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of: :

GUZI ET AL : Examiner: E. Huang

For Patent For: FARNESYL PROTEIN : Group Art Unit: 1625
TRANSFERASE INHIBITORS : Date: July 19, 2001

: :
Serial No.: 09/465,523 :

Filed: December 16, 1999 :
-----X

Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:


Submitted herewith is Applicants' 1449 form and a copy of the reference cited therein. Applicants request that these documents be made of record in the above-identified application.

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON

July 19, 2001
(DATE OF DEPOSIT)

HENRY C. JEANETTE REG. NO. 30,856
(REGISTERED REPRESENTATIVE)
Henry C. Jeanette July 19, 2001
(SIGNATURE AND DATE)

Respectfully submitted,


Henry C. Jeanette
Reg. No. 30, 856
Attorney for Applicants
(908) 298-5041